CAPITEL: Design and Implementation of a wireless 6 channel EMG measurement system for permanent in vivo use: in vitro results

Introduction Surface Electromyography of partial limb amputees is used to control prostheses. Implantable EMG systems offer a higher Signal to Noise Ratio (SNR) as well as improved muscle specificity, and a more convenient daily use. Material and methods We present a design for an implantable device (“implant”) with 6 channels, each suitable for an electrode array with 3 electrodes. The implant uses an ADS1298 analog front end with ADG2188 multiplexers for versatile electrode array configuration. The analog input is filtered with a balanced analog bandpass filter with corner frequencies of 30 and 800 Hz. The ADC sample rate is 2 KHz per channel, with 9 bits resolution. The dimensions of the PCB implant are 17.2 x 14.1x2.15 mm. To measure the SNR a sinusoidal signal with a peak to peak amplitude of 7 mV and a frequency of 200 Hz was applied to each input. To simulate muscle impedance, an equivalent muscle impedance model (Figure 1) was placed between the generator and each channel of the implant [1]. We have implemented two data transmission methods: wired duplex communication and wireless inductive link. The wired link is used to transfer raw data, while only the 6 EMG envelopes, with an update rate of 20 Hz, are sent via the wireless link. Results Each analog input channel performed with a SNR better than 52 dB, both for wired and wireless operation. Wired data was received successfully at 115200 bps and wireless data at 1080 bps. Discussion Our design achieves a high SNR and data rate. These early results are promising and we are packaging the PCBs for in-vivo testing. Conclusion We have demonstrated a very compact design suitable for the monitoring of 6 EMG channels, with options for raw data or EMG envelope transmission. [1] Kalvoy, H, 2009, doi: 10.1088/0967-3334/30/2/002

Underwater current leakage between encapsulated NiChrome tracks: Implications for strain-gauges and other implantable devices

We present the results of experiments aimed at identifying a suitable polymer for the encapsulation of thin-film strain gauges for underwater applications (with a view of using it in an instrumented bone fusion nail). The leakage currents across grooves cut (using a laser) in thin films of NiChrome over borosilicate glass were studied for encapsulated samples, immersed in water at 37 °C. The selected encapsulants were five silicone rubbers (of both medical and engineering grades), produced by Nusil (MED-6015, MED4-4220, MED3-4013, CV14-2500 and EPM-2420) and Elast-Eon™2A, a co-polymer developed by Aortech. The effect of a primer, as well as that of a black dye mixed with the rubber, was also investigated. 13% of samples exhibited slow current increases, peaking at 1–4 nA, and 9% exhibited brief peaks up to 30 nA (only one sample exhibited both). These were due to corrosion of the NiCr following ionic contamination. For the remaining 80%, the leakage current remained remarkably low (<1 nA). Silicone rubber encapsulation appears as a realistic low-cost alternative to the hermetic packaging of thin-film strain-gauges. However, this is conditional to achieving a suitable degree of cleanliness of all surfaces prior to encapsulation. Cleaning and rinsing procedures should therefore be evaluated before opting for this method

Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months

Copyright \ua9 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.OBJECTIVE: This study aimed to quantify the trajectory and magnitude of change of the key clinical features and corresponding symptom domains of dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD), including global cognition, parkinsonism, recurrent visual hallucinations, cognitive fluctuations, and sleep disturbance. METHODS: One hundred sixteen patients with Lewy body dementia (DLB = 72, PDD = 44) underwent assessment at baseline and 3 and 6 months as part of a prospective multicenter randomized controlled trial. Linear mixed models were constructed for core outcome measures using the Mini-Mental State Examination (MMSE), motor section of the Unified Parkinson\u27s Disease Rating Scale (UPDRS-III), Dementia Cognitive Fluctuations Scale (DCFS), and Neuropsychiatric Inventory (NPI). RESULTS: Within the time frame of our study (6 months), we were able to identify a significant cognitive decline of 1.3 points on the MMSE (p = 0.002) and significant worsening of motor parkinsonism with an increase in UPDRS-III score of 3.2 points (p = 0.018). Fluctuation severity also increased using the DCFS with a 6-month change in score of 1.3 points (p = 0.001). Uniquely, a signal for increased severity of sleep symptoms of 1.2 points (NPI-sleep) was also detectable (p = 0.04). Significant changes in neuropsychiatric symptoms were not detected. There was no difference in rates of change of scores between DLB and PDD. DISCUSSION: Clinically significant rates of change in core clinical features can be detected and quantified in Lewy body dementia over a relatively short period (6 months) using common clinical instruments and thus may be useful as clinical endpoints for therapeutic trials of disease-modifying and symptomatic agents

Nature of the Earth's earliest crust from hafnium isotopes in single detrital zircons

Continental crust forms from, and thus chemically depletes, the Earth's mantle. Evidence that the Earth's mantle was already chemically depleted by melting before the formation of today's oldest surviving crust has been presented in the form of Sm-Nd isotope studies of 3.8-4.0 billion years old rocks from Greenland(1-5) and Canada(5-7). But this interpretation has been questioned because of the possibility that subsequent perturbations may have re-equilibrated the neodymium-isotope compositions of these rocks(8). Independent and more robust evidence for the origin of the earliest crust and depletion of the Archaean mantle can potentially be provided by hafnium-isotope compositions of zircon, a mineral whose age can be precisely determined by U-Pb dating, and which can survive metamorphisms(4). But the amounts of hafnium in single zircon grains are too small for the isotopic composition to be precisely analysed by conventional methods. Here we report hafnium-isotope data, obtained using the new technique of multiple-collector plasma-source mass spectrometry(9), for 37 individual grains of the oldest known terrestrial zircons (from the Narryer Gneiss Complex, Australia, with U-Pb ages of up to 4.14 Gyr (refs 10-13)). We find that none of the grains has a depleted mantle signature, but that many were derived from a source with a hafnium-isotope composition similar to that of chondritic meteorites. Furthermore, more than half of the analysed grains seem to have formed by remelting of significantly older crust, indicating that crustal preservation and subsequent reworking might have been important processes from earliest times.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/62681/1/399252a0.pd

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials